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Finally, the new results raise a number
of questions about the mechanisms by
which clonally related ensembles are
formed. What molecular cues and
physical forces are responsible for the
various movements involved, such as
migration of the IPs, neurons, and astro-
cytes along the RGCs, bending of the
RGCs, and separation of the RGCs and
the neurons as the latter mature into full-
blown pyramidal neurons? Not only will
the answers to these questions illuminate
the molecular mechanisms by which
neuronal ensembles (and possibly cell as-
semblies) are formed, but they may pro-
vide clues to the origins of diseases in
which miswiring is known to play a central
role, including autism and schizophrenia.1504 Cell 157, June 19, 2014 ª2014 ElsevierACKNOWLEDGMENTS
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All well-known deleterious effects of angiotensin (Ang) II, including vasoconstriction, inflammation,
water and salt retention, and vascular remodeling, are mediated via its type 1 (AT1) receptor. This
explainswhy AT1 receptor blockers (ARBs) and inhibitors of Ang II synthesis, such as ACE inhibitors
and renin inhibitors, are beneficial for cardiovascular disease. Yet, Ang II has a second receptor, the
Ang II type 2 (AT2) receptor, the function of which, even after over 20 years of research, remains
largely unknown. In this issue, Marion et al. provide a new chapter to the AT2 receptor story.Previously, it was proposed that Ang II
type 2 (AT2) receptors antagonize the ef-
fect of the AT1 receptor, and that the
beneficial effects of ARBs could be due
to the stimulation of the unoccupied AT2
receptor. However, subsequent studies
revealed that AT2 receptors are not al-
ways protective (Verdonk et al., 2012a),
and the AT2 receptor agonist C21, at AT2
receptor-selective doses, does not lower
blood pressure (Verdonk et al., 2012b).
Of interest, AT2 receptors were shown to
stimulate neurite outgrowth, and AT2 in-hibitors to reduce pain signaling in animal
models and in rodent and human sensory
neurons in vitro (Anand et al., 2013)
(Figure 1A). As such, they are potential
targets for agonists in nerve regeneration
and for antagonists to suppress pain.
Recently, the latter concept has been
successfully tested in patients with post-
herpetic neuralgia, where the AT2 recep-
tor antagonist EMA401 in a randomized,
double-blind, placebo-controlled phase
2 trial significantly reduces pain over
4 weeks of treatment (Rice et al., 2014).This is the only human trial so far involving
drugs acting on AT2 receptors, which sug-
gests that AT2 receptor antagonists might
be further developed to treat neuropathic
pain.
In this issue of Cell, Marion et al. (2014)
now suggest that AT2 receptor stimulation
may induce analgesia. Following the
clinical observation that Mycobacterium
ulcerans, the etiological agent of Buruli
ulcer, causes extensive skin lesions that
are not accompanied by pain, they study
a mouse footpad model in which pain
Figure 1. Angiotensin II Formation and the Subsequent Activation of AT2 Receptors, Resulting in Either Hyperalgesia or Analgesia
(A) The hyperalgesia pathway predominates in peripheral primary nociceptors and converges with the nerve growth factor-TRPV1 (transient receptor potential
vanilloid subfamily member 1) pain pathway.
(B) The mycolactone analgesia pathway may predominate in inflammatory cells and central nervous system neurons. PLA2, phospholipase A2; AA, arachidonic
acid; COX-1, cyclooxygenase-1; PGE2, prostaglandin E2; TRAAK, TWIK-related, arachidonic acid-activated K
+ channel.responses are diminished, but the prox-
imal nerve shows no damage. Next, the
authors screen a siRNA library targeting
8,000 host genes, making use of
macrophage-like cells of the Raw267.4
cell line. They monitor cellular hyper-
polarization following exposure to myco-
lactone, the main toxin secreted by
M. ulcerans. Unexpectedly, this screening
only yields three receptors, of which the
AT2 receptor appears themost promising.
Subsequently, with the help of AT2 recep-
tor knockout mice and the AT2 recep-
tor antagonist PD123319, the authors
demonstrate a potential role for this re-
ceptor in nociception and the molecular
mechanism involved (Figure 1B). Myco-
lactone, at micromolar levels, is found
to bind both AT1 and AT2 receptors, but
can only activate the AT2 receptor. This
activation is Gai-dependent and leads to
phospholipase A2-mediated arachidonic
acid (AA) liberation and the generation
of prostaglandin E2 (PGE2) from AA
by cyclooxygenase-1 (COX-1). PGE2 can
cause neuronal hyperpolarization through
activation of the KCNK4 (TRAAK) K+
channel, thereby inducing analgesia.These findings, although exciting, raise
a number of questions. First, they oppose
the current view, supported by clinical ev-
idence, that AT2 receptor antagonism and
COX inhibition suppress pain, and that
COX-2, rather than COX-1, is upregulated
in inflammatory conditions. In fact, the
data from mice infected with M. ulcerans
and treated with the COX inhibitor piroxi-
cam further suggest that classical pain
suppressants like NSAIDs (which block
COX) would enhance pain in patients
with Buruli ulcer. Furthermore, TRAAK
activation by PGE2, rather than AA, is un-
usual (Noe¨l et al., 2011), and the observa-
tion that millimolar concentrations of the
K+ channel blockers tetraethylammonium
and BaCl2 prevent hyperpolarization is at
most suggestive for TRAAK involvement,
but not conclusive.
It should be mentioned that the molec-
ular studies are performed in neonatal
mouse hippocampal neurons, pheochro-
mocytoma cell 12 (PC12) cells, and
macrophage-like cells, but not in intact
animals or sensory neurons/nociceptors,
leaving open the question of where
exactly the AT2 receptor activation occursCell 15in the footpad afterM. ulcerans/mycolac-
tone injection. Surprisingly, there is no
alteration in footpad AT2 receptor density
following infection. One alternative expla-
nation might be that these AT2 receptors
are not neuronal, but located on non-
neuronal cells, such as macrophages or
fibroblasts, where they might exert anti-
inflammatory effects, such as suppress-
ing the release of cytokines (Rompe
et al., 2010). In addition, mycolactone-
dependent inhibition of protein transloca-
tion into the endoplasmic reticulum may
also explain the deficit of cytokines (Hall
et al., 2014). Such effects would explain
the lack of inflammation, and, thereby,
the lack of inflammatory pain sensation.
Previous animal model studies have re-
ported transient early hyperesthesia and
then hypoesthesia with nerve damage.
The latter is also observed in clinical skin
biopsies (Zavattaro et al., 2012), although
these published studies have not used
gold-standard methods to assess noci-
ceptors or pain receptors in affected cuta-
neous tissues. In this regard, it is of inter-
est to note that the cutaneous loss of
nociception in leprosy, also caused by a7, June 19, 2014 ª2014 Elsevier Inc. 1505
Mycobacterium (M. leprae), involves loss
of intraepidermal nerve fibers and pain re-
ceptors in clinical skin biopsies (Facer
et al., 2000). The absence of inflammatory
pain may thus result from effects of myco-
lactone on both inflammatory cells and
cutaneous nociceptors.
The mycolactone concentrations
required to stimulate AT2 receptors are
in the 3 mg/ml range (4 mmol/l), whereas
the level required to cause hyperpolar-
ization in vitro and that in the tissue after
infection are one to two orders of magni-
tude lower. Clearly, more evidence is
needed to confirm that mycolactone truly
is a bona fide AT2 receptor agonist at rele-
vant in vivo levels. It is also important to
know the exact location of the AT2 recep-
tors, and why mycolactone, despite bind-
ing to AT1 receptors, does not stimulate
these receptors. Studies with well-estab-
lished AT2 receptor agonists like C211506 Cell 157, June 19, 2014 ª2014 Elsevierand clinicopathological correlations may
help to answer these questions.ACKNOWLEDGMENTS
P.A. is a member of Spinifex Pharmaceuticals Sci-
entific Advisory Board and has participated in pre-
clinical and clinical studies with EMA401.REFERENCES
Anand, U., Facer, P., Yiangou, Y., Sinisi, M., Fox,
M., McCarthy, T., Bountra, C., Korchev, Y.E., and
Anand, P. (2013). Eur. J. Pain 17, 1012–1026.
Facer, P., Mann, D., Mathur, R., Pandya, S.,
Ladiwala, U., Singhal, B., Hongo, J., Sinicropi,
D.V., Terenghi, G., and Anand, P. (2000). Pain 85,
231–238.
Hall, B.S., Hill, K., McKenna, M., Ogbechi, J., High,
S., Willis, A.E., and Simmonds, R.E. (2014). PLoS
Pathog. 10, e1004061.
Marion, E., Song, O.-K., Christophe, T., Babon-
neau, J., Fenistein, D., Eyer, J., Letournel, F., Hen-Inc.rion, D., Clere, N., Paille, V., et al. (2014). Cell 157,
this issue, 1565–1576.
Noe¨l, J., Sandoz, G., and Lesage, F. (2011). Chan-
nels (Austin) 5, 402–409.
Rice, A.S., Dworkin, R.H., McCarthy, T.D., Anand,
P., Bountra, C., McCloud, P.I., Hill, J., Cutter, G.,
Kitson, G., Desem, N., and Raff, M.; EMA401-003
study group (2014). Lancet 383, 1637–1647.
Rompe, F., Artuc, M., Hallberg, A., Alterman, M.,
Stro¨der, K., Tho¨ne-Reineke, C., Reichenbach, A.,
Schacherl, J., Dahlo¨f, B., Bader, M., et al. (2010).
Hypertension 55, 924–931.
Verdonk, K., Danser, A.H.J., and van Esch, J.H.M.
(2012a). Expert Opin. Investig. Drugs 21, 501–513.
Verdonk, K., Durik, M., Abd-Alla, N., Batenburg,
W.W., van den Bogaerdt, A.J., van Veghel, R.,
Roks, A.J., Danser, A.H.J., and van Esch, J.H.M.
(2012b). Hypertension 60, 722–729.
Zavattaro, E., Boccafoschi, F., Borgogna, C.,
Conca, A., Johnson, R.C., Sopoh, G.E., Dossou,
A.D., Colombo, E., Clemente, C., Leigheb, G.,
and Valente, G. (2012). Histopathology 61,
224–236.Designer Proteins
to Trigger Cell Death
Wayne J. Fairbrother1,* and Avi Ashkenazi2,*
1Department of Early Discovery Biochemistry
2Cancer Immunology
Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA
*Correspondence: fairbrother.wayne@gene.com (W.J.F.), aa@gene.com (A.A.)
http://dx.doi.org/10.1016/j.cell.2014.06.010
Efforts to generate biologically active proteins by de novo computational design have been limited
to creating functional sites within pre-existing scaffolds. Procko et al. use an innovative com-
putational design approach coupled with in-vitro-targeted evolution to produce a potent polypep-
tide inhibitor of a viral Bcl-2-like protein. This novel inhibitor triggers apoptosis of virus-infected
cells.Metazoan organisms employ a distinct
type of programmed cell death, called
apoptosis, to eliminate severely damaged
or infected cells. The Bcl-2 gene family
encodes proteins that control apoptotic
signaling via the cell-intrinsic, mitochon-
drial pathway (Cory and Adams, 2002).
Two structural subclasses of this family
share Bcl-2 homology (BH) motifs: (1)
BH3 proteins (e.g., Bim, Bid, Bad, Bmf,Puma, and Noxa), which harbor a single
BH motif and promote apoptosis; and (2)
multi-BH proteins, which possess three
or four BH regions and act either as
apoptosis activators (e.g., Bax and Bak)
or inhibitors (e.g., Bcl-2, Bcl-xL, Bcl-w,
and Mcl-1). Some BH3 factors promote
apoptosis by sequestering prosurvival
Bcl-2 proteins from Bax and Bak,
whereas others bind directly to Bax orBak to drive activation. The BH3 motif—
an 26 amino acid a-helical peptide—
interacts with a hydrophobic groove on
the cognate binding partner.
Viruses often encode orthologs of
cellular antiapoptotic proteins to prevent
host cell death and extend viral repli-
cation. Epstein-Barr virus (EBV) latently
infects human B cells, contributing to
cancers such as Burkitt’s lymphoma.
